Inclusion Criteria

Key Inclusion Criteria (Part 2):

- Histopathologically or cytologically confirmed solid tumor that is refractory to
standard therapies, or for which no standard therapies exist, or for which the
Investigator feels no other active therapy is required for the duration of the study.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.

- Estimated life expectancy of greater than or equal to 3 months.

- Patient must have a tumor that is accessible for biopsy and must consent to paired
tumor biopsies and normal skin biopsies being taken pre- and post-dose of study drug.

- Additional criteria exist.

Key Exclusion Criteria (Part 2):

- Uncontrolled or symptomatic brain metastases.

- Use of investigational drug or device within 30 days prior to first dose of study
drug.

- Major surgery within 30 days prior to study start.

- Radiotherapy or chemotherapy within 21 days prior to study start (not including
palliative radiotherapy at focal sites).

- Pregnancy or lactation.

- Known positive serology for the human immunodeficiency virus (HIV), hepatitis B
and/or hepatitis C.

- Additional criteria exist.